目的 探讨氨磺必利对首发精神分裂症患者认知功能的影响.方法 对64例首发精神分裂症患者,按抛币法随机分为两组,分别给予氨磺必利和利培酮治疗,疗程12周.在治疗前及治疗后2,4,8,12周末分别采用阳性与阴性症状量表(PANSS),副反应量表(TESS)评定疗效和不良反应;治疗前后采用韦氏成人记忆量表(WMS-RC),威斯康星卡片分类测验(WCST),连线测验A和B等进行认知功能评定,并与正常对照组比较.结果 治疗12周后,氨磺必利组和利培酮组的PANSS总分分别为(44.7±6.7)分,(45.2±7.4)分,与治疗前比较均差异有统计学意义(P<0.01),两组间比较差异无统计学意义(P>0.05).治疗前,两患者组WMS-RC的长时记忆,短时记忆,瞬时记忆,记忆商(QM),WCST的持续错误数(Rpe),持续应答数(Rp),完成第一个分类所需应答数(R1st)和完成分类数(Cc)及TAT-A,TAT-B受损明显,与对照组比较均差异有统计学意义(P<0.05或<0.01).治疗12周后,患者组WMS-RC的再认,联想,理解,背数,记忆商(QM),及TAT-A,TAT-B与治疗前比较均明显改善接近正常(均P>0.05);患者组WCST的Rpe,Rp,R1st,Cc评分[氨磺必利组分别为(20.63 ±13.06)分,(28.75±15.72)分,(43.17±22.13)分,(3.62±2.21)分.利培酮组分别为(20.41±13.82)分,(29.31±16.12)分,(42.78±21.42)分,(3.67±2.32)分.]与正常对照组比较均差异有统计学意义(均P<0.05).两组间治疗前后认知功能各项评分比较无统计学意义(均P>0.05).结论 氨磺必利治疗精神分裂症疗效肯定,与利培酮相当,对精神分裂症的认知功能缺陷有改善作用.
目的 探討氨磺必利對首髮精神分裂癥患者認知功能的影響.方法 對64例首髮精神分裂癥患者,按拋幣法隨機分為兩組,分彆給予氨磺必利和利培酮治療,療程12週.在治療前及治療後2,4,8,12週末分彆採用暘性與陰性癥狀量錶(PANSS),副反應量錶(TESS)評定療效和不良反應;治療前後採用韋氏成人記憶量錶(WMS-RC),威斯康星卡片分類測驗(WCST),連線測驗A和B等進行認知功能評定,併與正常對照組比較.結果 治療12週後,氨磺必利組和利培酮組的PANSS總分分彆為(44.7±6.7)分,(45.2±7.4)分,與治療前比較均差異有統計學意義(P<0.01),兩組間比較差異無統計學意義(P>0.05).治療前,兩患者組WMS-RC的長時記憶,短時記憶,瞬時記憶,記憶商(QM),WCST的持續錯誤數(Rpe),持續應答數(Rp),完成第一箇分類所需應答數(R1st)和完成分類數(Cc)及TAT-A,TAT-B受損明顯,與對照組比較均差異有統計學意義(P<0.05或<0.01).治療12週後,患者組WMS-RC的再認,聯想,理解,揹數,記憶商(QM),及TAT-A,TAT-B與治療前比較均明顯改善接近正常(均P>0.05);患者組WCST的Rpe,Rp,R1st,Cc評分[氨磺必利組分彆為(20.63 ±13.06)分,(28.75±15.72)分,(43.17±22.13)分,(3.62±2.21)分.利培酮組分彆為(20.41±13.82)分,(29.31±16.12)分,(42.78±21.42)分,(3.67±2.32)分.]與正常對照組比較均差異有統計學意義(均P<0.05).兩組間治療前後認知功能各項評分比較無統計學意義(均P>0.05).結論 氨磺必利治療精神分裂癥療效肯定,與利培酮相噹,對精神分裂癥的認知功能缺陷有改善作用.
목적 탐토안광필리대수발정신분렬증환자인지공능적영향.방법 대64례수발정신분렬증환자,안포폐법수궤분위량조,분별급여안광필리화리배동치료,료정12주.재치료전급치료후2,4,8,12주말분별채용양성여음성증상량표(PANSS),부반응량표(TESS)평정료효화불량반응;치료전후채용위씨성인기억량표(WMS-RC),위사강성잡편분류측험(WCST),련선측험A화B등진행인지공능평정,병여정상대조조비교.결과 치료12주후,안광필리조화리배동조적PANSS총분분별위(44.7±6.7)분,(45.2±7.4)분,여치료전비교균차이유통계학의의(P<0.01),량조간비교차이무통계학의의(P>0.05).치료전,량환자조WMS-RC적장시기억,단시기억,순시기억,기억상(QM),WCST적지속착오수(Rpe),지속응답수(Rp),완성제일개분류소수응답수(R1st)화완성분류수(Cc)급TAT-A,TAT-B수손명현,여대조조비교균차이유통계학의의(P<0.05혹<0.01).치료12주후,환자조WMS-RC적재인,련상,리해,배수,기억상(QM),급TAT-A,TAT-B여치료전비교균명현개선접근정상(균P>0.05);환자조WCST적Rpe,Rp,R1st,Cc평분[안광필리조분별위(20.63 ±13.06)분,(28.75±15.72)분,(43.17±22.13)분,(3.62±2.21)분.리배동조분별위(20.41±13.82)분,(29.31±16.12)분,(42.78±21.42)분,(3.67±2.32)분.]여정상대조조비교균차이유통계학의의(균P<0.05).량조간치료전후인지공능각항평분비교무통계학의의(균P>0.05).결론 안광필리치료정신분렬증료효긍정,여리배동상당,대정신분렬증적인지공능결함유개선작용.
Objective To explore the effects of amisulpride on the cognitive function in first-episode schizophrenia patients.Methods 64 patients in first-episode schizophrenia were divided into two groups randomly according to the method of tossing a coin,then treated with amisulpride or risperidone respectively for 12 weeks.The efficacy and adverse effect were evaluated with positive and negative scale (PANSS) and treatment emergent side effect scale (TESS) before treatment and after treatment for 2 weeks,4 weeks,8 weeks,12 weeks.Before and after treatment for 12 weeks,cognitive function of all the patients was blindly evaluated with Wechsler Scale-revised China (WMS-RC),Wisconsin Card Sorting Test(WCST) and Trail Making test A and B.Results After 12-week treatment,statistical difference was found in amisulpride(44.7 ± 6.7) and risperidone (45.2 ± 7.4) groups (P < 0.01).But no statistical difference was found between the two groups (P > 0.05).The cognitive function in firstepisode schizophrenia was damaged obviously.In two groups,the scores in recognize,association,comprehend,back a few and MQ of WMS and TAT-A,TAT-B were improved significantly after treatment for 12 weeks (P > 0.05).These items of WCST were improved more remarkably than baseline (amisulpride (20.63 ± 13.06),(28.75 ± 15.72),(43.17 ±22.13),(3.62 ±2.21),P<0.05; risperidone(20.41 ±13.82),(29.31 ± 16.12),(42.78 ± 21.42),(3.67 ± 2.32),P < 0.05).The improvement in the scores of WCST were statistical difference compared with control group(P < 0.05).But statistical difference was no found between the two groups (P > 0.05).Conclusion The study shows that the cognitive dysfunction in first-episode schizophrenia can be improved by amisulpride,and the efficacy was similar with risperidone.